Authors' objectives: Lymphoma is a cancer of the lymphatic system, which is part of the immune system. The lymphatic system contains cells called lymphocytes that fight infections. Diffuse large B-cell lymphoma is the most common type of lymphoma. It can occur at any age but is more common in those over 65 years of age. Everolimus is a new drug for diffuse large B-cell lymphoma taken as a tablet once a day. Some studies have suggested everolimus may be helpful in preventing the cancer from coming back in people whose first treatment with chemotherapy has worked. If everolimus is licensed for use in the UK, it could be a new treatment option for diffuse large B-cell lymphoma that may reduce symptoms of the disease and improve survival.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/everolimus-afinitor-for-diffuse-large-b-cell-lymphoma-maintenance-therapy/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)